由DNA疫苗诱导的HIV-1特异性细胞介导的免疫反应通过甘露糖包被的脂质体得到增强，并被抗干扰素-γ抗体抑制。
HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody.
作者信息
Toda S, Ishii N, Okada E, Kusakabe K I, Arai H, Hamajima K, Gorai I, Nishioka K, Okuda K
机构信息
Department of Bacteriology, Yokohama City University School of Medicine, Japan.
出版信息
Immunology. 1997 Sep;92(1):111-7. doi: 10.1046/j.1365-2567.1997.00307.x.
Abstract
The adjuvant effect of mannan-coated liposomes on human immunodeficiency virus type-1 (HIV-1) DNA vaccine and the mechanism of this enhancement were studied. Coating of cationic liposomes with mannan significantly enhanced the ability of this vaccine to induce an HIV-specific delayed-type hypersensitivity (DTH) response. HIV-specific cytotoxic T-cell (CTL) activity elicited by DNA vaccination was also significantly enhanced with the mannan-liposome cocktail. This mannan-liposome-mediated activity was greatly inhibited by in vivo injection of anti-interferon (IFN)-gamma antibody, which suggests that IFN-gamma plays an important role in this HIV-specific immune response. The results of both isotype-specific antibody and cytokine analysis revealed that mannan-liposome-mediated DNA vaccination enhances Th1-mediated immunity.
摘要
研究了甘露聚糖包被的脂质体对1型人类免疫缺陷病毒（HIV-1）DNA疫苗的佐剂作用及其增强机制。用甘露聚糖包被阳离子脂质体可显著增强该疫苗诱导HIV特异性迟发型超敏反应（DTH）的能力。甘露聚糖-脂质体混合物也显著增强了DNA疫苗引发的HIV特异性细胞毒性T细胞（CTL）活性。体内注射抗干扰素（IFN）-γ抗体可大大抑制这种甘露聚糖-脂质体介导的活性，这表明IFN-γ在这种HIV特异性免疫反应中起重要作用。同型特异性抗体和细胞因子分析结果均显示，甘露聚糖-脂质体介导的DNA疫苗接种可增强Th1介导的免疫。
相似文献
1
HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody.
Immunology. 1997 Sep;92(1):111-7. doi: 10.1046/j.1365-2567.1997.00307.x.
2
Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine.
Eur J Immunol. 1997 Dec;27(12):3121-9. doi: 10.1002/eji.1830271207.
3
Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system.
Immunology. 2001 May;103(1):98-105. doi: 10.1046/j.1365-2567.2001.01201.x.
4
HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.
Immunology. 1997 Jan;90(1):1-6. doi: 10.1046/j.1365-2567.1997.00117.x.
5
Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Virus Res. 2006 Mar;116(1-2):11-20. doi: 10.1016/j.virusres.2005.08.008. Epub 2005 Oct 7.
6
IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine.
Vaccine. 1999 Feb 26;17(7-8):858-66. doi: 10.1016/s0264-410x(98)00271-0.
7
Enhanced non-inflammasome mediated immune responses by mannosylated zwitterionic-based cationic liposomes for HIV DNA vaccines.
Biomaterials. 2016 Apr;85:1-17. doi: 10.1016/j.biomaterials.2016.01.054. Epub 2016 Jan 29.
8
Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines.
AIDS Res Hum Retroviruses. 1998 Mar 20;14(5):409-17. doi: 10.1089/aid.1998.14.409.
9
Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response.
Clin Immunol Immunopathol. 1998 Aug;88(2):205-10. doi: 10.1006/clin.1998.4566.
10
Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1.
AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1421-8. doi: 10.1089/aid.1997.13.1421.
引用本文的文献
1
Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral diseases.
J Control Release. 2023 Jun;358:476-497. doi: 10.1016/j.jconrel.2023.05.010. Epub 2023 May 14.
2
Liposomal Formulations of a Polyleucine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer.
Pharmaceutics. 2023 Feb 10;15(2):602. doi: 10.3390/pharmaceutics15020602.
3
Mannose-Modified Chitosan-Nanoparticle-Based Subunit OralVaccine-Induced Immune Response and Efficacy in a Challenge Trial in Broilers.
Vaccines (Basel). 2020 Jun 11;8(2):299. doi: 10.3390/vaccines8020299.
4
Biodegradable polymers for modern vaccine development.
J Ind Eng Chem. 2019 Sep 25;77:12-24. doi: 10.1016/j.jiec.2019.04.044. Epub 2019 Apr 28.
5
Nanomedicine Strategies to Target Tumor-Associated Macrophages.
Int J Mol Sci. 2017 May 4;18(5):979. doi: 10.3390/ijms18050979.
6
Yeast Surface Display of Two Proteins Previously Shown to Be Protective Against White Spot Syndrome Virus (WSSV) in Shrimp.
PLoS One. 2015 Jun 17;10(6):e0128764. doi: 10.1371/journal.pone.0128764. eCollection 2015.
7
Dendritic cell immunotherapy: clinical outcomes.
Clin Transl Immunology. 2014 Jul 18;3(7):e21. doi: 10.1038/cti.2014.14. eCollection 2014 Jul.
8
Modulation of HIV-1 immunity by adjuvants.
Curr Opin HIV AIDS. 2014 May;9(3):242-9. doi: 10.1097/COH.0000000000000052.
9
Targeting antigens to dendritic cell receptors for vaccine development.
J Drug Deliv. 2013;2013:869718. doi: 10.1155/2013/869718. Epub 2013 Oct 8.
10
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.
Biomaterials. 2013 Aug;34(26):6202-28. doi: 10.1016/j.biomaterials.2013.05.012. Epub 2013 May 28.
本文引用的文献
1
2
Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes.
Infect Immun. 1996 Jun;64(6):1961-7. doi: 10.1128/iai.64.6.1961-1967.1996.
3
Protective immunity against HIV infection: has nature done the experiment for us?
Immunol Today. 1996 Jan;17(1):21-4. doi: 10.1016/0167-5699(96)80564-0.
4
IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses.
Immunity. 1996 May;4(5):471-81. doi: 10.1016/s1074-7613(00)80413-6.
5
DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein.
Hum Gene Ther. 1995 Nov;6(11):1447-56. doi: 10.1089/hum.1995.6.11-1447.
6
Interleukin 12 in combination with anti-interleukin 10 reverses graft prolongation after portal venous immunization.
Transplantation. 1995 Dec 15;60(11):1337-41.
7
IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.
J Immunol. 1993 Aug 15;151(4):1938-49.
8
A strategy for prophylactic vaccination against HIV.
Science. 1993 May 28;260(5112):1270-2. doi: 10.1126/science.8098553.
9
Individual cells simultaneously produce both IL-4 and IL-6 in vivo.
Cytokine. 1994 May;6(3):329-36. doi: 10.1016/1043-4666(94)90030-2.
10
Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma.
J Immunol. 1994 Feb 15;152(4):1883-7.
Zotero 插件